Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Urine Periostin Level and Renal Function in Malignancy Patients Treated with High-Dose Cisplatine

Folia Medica Indonesiana · Vol. 60 No. 4 (2024) · hlm. 310–316

DOI
10.20473/fmi.v60i4.63357
ISSN
2355-8393, 2599-056X
Terbit
2024-12-11
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Cisplatin has been used extensively as a cancer treatment. Nephrotoxicity, which is assessed by blood urea levels, blood creatinine, and estimated glomerular filtration rate (eGFR), is caused by cisplatin metabolites that build up in the kidneys. Because of these indicators' numerous flaws, optimal biological markers are required. One of the key mediators of inflammatory processes, such as kidney fibrosis and inflammation, is periostin. In cancer patients undergoing high-dose cisplatin therapy, the purpose of this study is to ascertain how urine periostin changes and how it relates to kidney function. This cross-sectional study was carried out at the National Center General Hospital of Cipto Mangunkusumo's medical hematology-oncology outer clinic and medical hematology-oncology ward on the eighth floor starting in November 2019 and ending when the minimum sample was obtained through consecutive sampling. Data was analyzed by IBM SPSS Statistics for Windows version 23.0 based on the research objective. Of the 37 responders, 70.3% were men, 29.7% were between the ages of 41 and 50, 78.4% were married, 59.5% had completed high school, 37.8% were employed, 59.5% had NPC, and 64.9% had a Karnofsky score of 80. Between before and one week following chemotherapy II, the respondents' blood creatinine and urea levels rose. The eGFR value has also decreased. Periostin levels, on the other hand, tended to rise one week following treatment III after declining during chemotherapy I and II (p value>0.05). Urine periostin levels and other kidney function indicators did not significantly correlate (p>0.05), according to the correlation test, and several domains had negative directions. The correlation coefficient values were modest (r = 0.017-0.254). There is a changing of urine periostin level of malignant patients receiving high dose cisplatin therapy which increase after the third chemotherapy. No significant correlation was found between periostin levels and kidney function in malignant patients with high-dose cisplatin therapy.

Kata kunci

Jaringan kolaborasi para penulis

11 penulis · 23 tautan kepenulisan bersama · 8 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Universitas Airlangga
  • Diponegoro University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Aditia R.R.Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Indra WijayaDiponegoro University1
Cosphiadi IrawanRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Sukamto KoesnoeRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Arifa MustikaUniversitas Airlangga1
Mochammad ThahaUniversitas Airlangga1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Urine Periostin Level and Renal Function in Malignancy Patients Treated with High-Dose Cisplatine</dc:title><dc:creator>Harry Yusuf</dc:creator><dc:creator>Andhika Rachman</dc:creator><dc:creator>Maruhum Bonar Hasiholan Marbun</dc:creator><dc:creator>Hamzah Shatri</dc:creator><dc:creator>Putri Aliya Ahadini</dc:creator><dc:subject>periostin</dc:subject><dc:subject>urinary biomarkers</dc:subject><dc:subject>cisplatin nephrotoxicity</dc:subject><dc:subject>high-dose cisplatin</dc:subject><dc:subject>renal function</dc:subject><dc:subject>estimated glomerular filtration rate</dc:subject><dc:subject>creatinine</dc:subject><dc:subject>blood urea</dc:subject><dc:subject>non-small cell lung cancer</dc:subject><dc:subject>chemotherapy-induced kidney injury</dc:subject><dc:subject>renal fibrosis</dc:subject><dc:description xml:lang="en">Cisplatin has been used extensively as a cancer treatment. Nephrotoxicity, which is assessed by blood urea levels, blood creatinine, and estimated glomerular filtration rate (eGFR), is caused by cisplatin metabolites that build up in the kidneys. Because of these indicators' numerous flaws, optimal biological markers are required. One of the key mediators of inflammatory processes, such as kidney fibrosis and inflammation, is periostin. In cancer patients undergoing high-dose cisplatin therapy, the purpose of this study is to ascertain how urine periostin changes and how it relates to kidney function. This cross-sectional study was carried out at the National Center General Hospital of Cipto Mangunkusumo's medical hematology-oncology outer clinic and medical hematology-oncology ward on the eighth floor starting in November 2019 and ending when the minimum sample was obtained through consecutive sampling. Data was analyzed by IBM SPSS Statistics for Windows version 23.0 based on the research objective. Of the 37 responders, 70.3% were men, 29.7% were between the ages of 41 and 50, 78.4% were married, 59.5% had completed high school, 37.8% were employed, 59.5% had NPC, and 64.9% had a Karnofsky score of 80. Between before and one week following chemotherapy II, the respondents' blood creatinine and urea levels rose. The eGFR value has also decreased. Periostin levels, on the other hand, tended to rise one week following treatment III after declining during chemotherapy I and II (p value&gt;0.05). Urine periostin levels and other kidney function indicators did not significantly correlate (p&gt;0.05), according to the correlation test, and several domains had negative directions. The correlation coefficient values were modest (r = 0.017-0.254). There is a changing of urine periostin level of malignant patients receiving high dose cisplatin therapy which increase after the third chemotherapy. No significant correlation was found between periostin levels and kidney function in malignant patients with high-dose cisplatin therapy.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2024-12-11</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v60i4.63357</dc:identifier><dc:identifier>10.20473/fmi.v60i4.63357</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 60 No 4 (2024); 310-316</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/63357/30866</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>